

# Janne Backman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6977974/publications.pdf>

Version: 2024-02-01

187  
papers

13,853  
citations

14614

66  
h-index

23472

111  
g-index

188  
all docs

188  
docs citations

188  
times ranked

8922  
citing authors

#	ARTICLE	IF	CITATIONS
1	Translational aspects of cytochrome P450-mediated drug-drug interactions: A case study with clopidogrel. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 130, 48-59.	1.2	3
2	Pharmacogenomics of celiprolol - evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics. <i>Clinical and Translational Science</i> , 2022, 15, 409-421.	1.5	4
3	Systemic hypertonic saline enhances glymphatic spinal cord delivery of lumbar intrathecal morphine. <i>Journal of Controlled Release</i> , 2022, 344, 214-224.	4.8	9
4	Healthcare costs and mortality associated with serious fluoroquinolone-related adverse reactions. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00931.	1.1	4
5	Medicines, environment and clinical pharmacology. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 131, 149-152.	1.2	2
6	Genomewide Association Study of Simvastatin Pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 676-686.	2.3	14
7	Relationship of Edoxaban Plasma Concentration and Blood Coagulation in Healthy Volunteers Using Standard Laboratory Tests and Viscoelastic Analysis. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 522-530.	1.0	2
8	Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 643-650.	0.8	11
9	Health service use and costs associated with fluoroquinolone-related tendon injuries. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00796.	1.1	7
10	An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes - application to establishing CYP2C8 inhibitor selectivity. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 162, 105810.	1.9	7
11	Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1622-1632.	2.3	20
12	Rifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers. <i>Anesthesia and Analgesia</i> , 2021, 133, 423-434.	1.1	1
13	Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation - A Potentially Beneficial Drug-Drug Interaction. <i>Clinical and Translational Science</i> , 2020, 13, 345-351.	1.5	25
14	Comparison of LC-MS/MS and chemiluminescent immunoassays for immunosuppressive drugs reveals organ dependent variation in blood cyclosporine a concentrations. <i>Clinica Chimica Acta</i> , 2020, 508, 22-27.	0.5	7
15	Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin. <i>Clinical and Translational Science</i> , 2020, 13, 1236-1243.	1.5	20
16	UGT1A3 and Sex Are Major Determinants of Telmisartan Pharmacokinetics - A Comprehensive Pharmacogenomic Study. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 885-895.	2.3	11
17	Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-Lasting Inhibition of CYP2C19. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1254-1264.	2.3	13
18	CYP3A4 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 448-457.	2.3	22

#	ARTICLE	IF	CITATIONS
19	Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 2013-2019.	1.3	21
20	Dexmedetomidine enhances glymphatic brain delivery of intrathecally administered drugs. <i>Journal of Controlled Release</i> , 2019, 304, 29-38.	4.8	73
21	Enantiospecific Pharmacogenomics of Fluvastatin. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 668-680.	2.3	26
22	Fluoroquinolone-related adverse events resulting in health service use and costs: A systematic review. <i>PLoS ONE</i> , 2019, 14, e0216029.	1.1	23
23	Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1345-1361.	2.3	107
24	Critical Differences between Enzyme Sources in Sensitivity to Detect Time-Dependent Inactivation of CYP2C8. <i>Drug Metabolism and Disposition</i> , 2019, 47, 436-443.	1.7	7
25	Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. <i>Drug Metabolism and Disposition</i> , 2019, 47, 377-385.	1.7	15
26	Response to Interaction of Dasabuvir With Clopidogrel: Did Predictions by Physiologically Based Pharmacokinetics Modeling Pass the Test? <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 322-322.	2.3	1
27	Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 219-228.	2.3	51
28	Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice. <i>International Journal of Pharmaceutics</i> , 2018, 544, 121-128.	2.6	9
29	Implications of intercorrelation between hepatic CYP3A4 and CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 972-986.	1.1	19
30	Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 341-345.	1.2	12
31	Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 158-168.	2.3	19
32	Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 495-504.	2.3	14
33	Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 417-432.	2.9	48
34	Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2018, 46, 141-150.	1.7	22
35	Voriconazole greatly increases the exposure to oral buprenorphine. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1615-1622.	0.8	12
36	Cytochrome P450 in Pharmacogenetics: An Update. <i>Advances in Pharmacology</i> , 2018, 83, 3-32.	1.2	113

#	ARTICLE	IF	CITATIONS
37	In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 739-748.	1.2	14
38	Implications of inter-correlation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide and gemfibrozil. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO2-13-2.	0.0	0
39	Simvastatin pre-treatment improves survival and mitochondrial function in a 3-day fluid-resuscitated rat model of sepsis. <i>Clinical Science</i> , 2017, 131, 747-758.	1.8	12
40	UDP-glucuronosyltransferase catalyzed drug bioactivation: Mechanisms and potential for clinically significant drug-drug interactions. <i>Drug Metabolism and Pharmacokinetics</i> , 2017, 32, S20.	1.1	0
41	Pilot Study of Propofol-induced Slow Waves as a Pharmacologic Test for Brain Dysfunction after Brain Injury. <i>Anesthesiology</i> , 2017, 126, 94-103.	1.3	12
42	Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 83-95.	1.5	30
43	Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1364-1371.	1.7	30
44	Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects. <i>Pharmacology Research and Perspectives</i> , 2016, 4, e00271.	1.1	9
45	Using Hilbert-Huang Transform to assess EEG slow wave activity during anesthesia in post-cardiac arrest patients. , 2016, 2016, 1850-1853.		2
46	Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1363-1371.	0.8	15
47	VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 13144-13149.	3.3	98
48	Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 313-315.	1.1	20
49	Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. <i>Pharmacological Reviews</i> , 2016, 68, 168-241.	7.1	175
50	Intravenous Lipid Emulsion Given to Volunteers does not Affect Symptoms of Lidocaine Brain Toxicity. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 116, 378-383.	1.2	43
51	Effect of carboxylesterase 1 c.428C>>A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1131-1138.	1.1	35
52	Drug-Related Inadvertent Deaths in a University Hospital - A Declining Trend. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 421-426.	1.2	22
53	SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 382-387.	0.7	122
54	Targeting matrix metalloproteinases with intravenous doxycycline in severe sepsis - A randomised placebo-controlled pilot trial. <i>Pharmacological Research</i> , 2015, 99, 44-51.	3.1	10

#	ARTICLE	IF	CITATIONS
55	Effect of grapefruit juice on the bioactivation of prasugrel. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 139-145.	1.1	13
56	Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 321-327.	0.8	30
57	Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 441-447.	0.8	69
58	Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 650-658.	2.3	70
59	Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate Simvastatin. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1655-1660.	1.7	25
60	Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug-Drug Interactions. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 498-507.	2.3	124
61	Paroxetine Markedly Increases Plasma Concentrations of Ophthalmic Timolol; CYP2D6 Inhibitors May Increase the Risk of Cardiovascular Adverse Effects of 0.5% Timolol Eye Drops. <i>Drug Metabolism and Disposition</i> , 2014, 42, 2068-2076.	1.7	9
62	Effect of Simvastatin on Physiological and Biological Outcomes in Patients Undergoing Esophagectomy. <i>Annals of Surgery</i> , 2014, 259, 26-31.	2.1	42
63	Grapefruit Juice Inhibits the Metabolic Activation of Clopidogrel. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 307-313.	2.3	49
64	In Vitro Assessment of Time-Dependent Inhibitory Effects on CYP2C8 and CYP3A Activity by Fourteen Protein Kinase Inhibitors. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1202-1209.	1.7	56
65	Autoinhibition of CYP3A4 Leads to Important Role of CYP2C8 in Imatinib Metabolism: Variability in CYP2C8 Activity May Alter Plasma Concentrations and Response. <i>Drug Metabolism and Disposition</i> , 2013, 41, 50-59.	1.7	57
66	Gemfibrozil Impairs Imatinib Absorption and Inhibits the CYP2C8-Mediated Formation of Its Main Metabolite. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 383-393.	2.3	28
67	Intravenous Lipid Emulsion Entraps Amitriptyline into Plasma and Can Lower its Brain Concentration – An Experimental Intoxication Study in Pigs. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013, 113, 193-200.	1.2	45
68	A Time-to-Event Model for Acute Rejections in Paediatric Renal Transplant Recipients Treated with Cyclosporin A. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, n/a-n/a.	1.1	14
69	Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1488-1496.	1.1	32
70	SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 19-24.	0.7	36
71	Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Cyclosporin. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 347-360.	1.0	16
72	Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 846-855.	2.3	36

#	ARTICLE	IF	CITATIONS
73	Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 312-322.	4.0	85
74	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. <i>British Journal of Pharmacology</i> , 2012, 165, 2787-2798.	2.7	74
75	Carboxylesterase 1 Polymorphism Impairs Oseltamivir Bioactivation in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 68-71.	2.3	64
76	Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 681-688.	0.8	13
77	CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 257-267.	1.1	39
78	Gender, but not <i>CYP7A1</i> or <i>SLCO1B1</i> Polymorphism, Affects the Fasting Plasma Concentrations of Bile Acids in Human Beings. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 110, 245-252.	1.2	37
79	Itraconazole, a P-Glycoprotein and CYP3A4 Inhibitor, Markedly Raises the Plasma Concentrations and Enhances the Renin-Inhibiting Effect of Aliskiren. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 359-367.	1.0	54
80	Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 579-586.	2.3	50
81	The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 151-155.	0.8	12
82	No significant effect of the <i>SLCO1B1</i> polymorphism on the pharmacokinetics of ursodeoxycholic acid. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 1159-1167.	0.8	6
83	Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1977-1986.	1.7	58
84	Reevaluation of the Microsomal Metabolism of Montelukast: Major Contribution by CYP2C8 at Clinically Relevant Concentrations. <i>Drug Metabolism and Disposition</i> , 2011, 39, 904-911.	1.7	42
85	Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 223-230.	2.3	54
86	Long-Term Changes in Cyclosporine Pharmacokinetics After Renal Transplantation in Children: Evidence for Saturable Presystemic Metabolism and Effect of <i>NR1I2</i> Polymorphism. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 581-597.	1.0	25
87	Simvastatin Decreases Lipopolysaccharide-induced Pulmonary Inflammation in Healthy Volunteers. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 1107-1114.	2.5	221
88	No significant effect of <i>ABCB1</i> haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 207-213.	1.1	52
89	CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe. <i>Drug Metabolism and Disposition</i> , 2009, 37, 2359-2366.	1.7	49
90	Effect of <i>SLCO1B1</i> polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 447-457.	0.7	56

#	ARTICLE	IF	CITATIONS
91	Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 17-24.	0.8	42
92	Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 511-519.	0.8	16
93	<i>In vitro</i> Inhibition of CYP1A2 by Model Inhibitors, Anti-inflammatory Analgesics and Female Sex Steroids: Predictability of <i>in vivo</i> Interactions. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 103, 157-165.	1.2	41
94	The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 403-411.	2.3	79
95	Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 488-496.	2.3	71
96	Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin. <i>Clinical Pharmacokinetics</i> , 2008, 47, 463-474.	1.6	177
97	Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. <i>Pharmacogenomics Journal</i> , 2008, 8, 268-277.	0.9	59
98	Trimethoprim and the <i>CYP2C8</i> <sup>*3</sup> Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone. <i>Drug Metabolism and Disposition</i> , 2008, 36, 73-80.	1.7	110
99	Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 77-90.	0.7	71
100	Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 937-942.	0.7	59
101	Effects of Daily Ingestion of Cranberry Juice on the Pharmacokinetics of Warfarin, Tizanidine, and Midazolam—Probes of CYP2C9, CYP1A2, and CYP3A4. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 833-839.	2.3	84
102	Developmental pharmacokinetics of ciclosporin—a population pharmacokinetic study in paediatric renal transplant candidates. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 772-784.	1.1	54
103	Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 463-469.	0.8	34
104	Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 829-836.	0.8	13
105	Polymorphisms of COX-1 and GP VI associate with the antiplatelet effect of aspirin in coronary artery disease patients. <i>Thrombosis and Haemostasis</i> , 2006, 95, 253-259.	1.8	110
106	Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 801-808.	0.7	96
107	Differential Inhibition of Cytochrome P450 3A4, 3A5 and 3A7 by Five Human Immunodeficiency Virus (HIV) Protease Inhibitors in vitro. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 98, 79-85.	1.2	100
108	Pioglitazone is Metabolised by CYP2C8 and CYP3A4 in vitro: Potential for Interactions with CYP2C8 Inhibitors. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 99, 44-51.	1.2	123

#	ARTICLE	IF	CITATIONS
109	Effect of rifampicin on the pharmacokinetics of pioglitazone. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 70-78.	1.1	75
110	Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 345-357.	1.1	62
111	Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 231-242.	2.3	44
112	Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 565-581.	2.3	705
113	Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 217-223.	0.8	32
114	Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 409-415.	0.8	106
115	Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 451-461.	0.8	59
116	Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 463-472.	0.8	79
117	Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 503-509.	0.8	30
118	The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 645-651.	0.8	24
119	Rofecoxib Is a Potent, Metabolism-Dependent Inhibitor of CYP1A2: Implications for in Vitro Prediction of Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2006, 34, 2091-2096.	1.7	37
120	Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 303-309.	0.7	112
121	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 404-414.	2.3	99
122	Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 468-478.	2.3	320
123	Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 154-167.	2.3	132
124	Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 400-411.	2.3	87
125	Cyclosporine markedly raises the plasma concentrations of repaglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 388-399.	2.3	180
126	Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 433-439.	1.1	40



#	ARTICLE	IF	CITATIONS
127	Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 208-217.	1.1	36
128	Comparison of 3-Hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors (Statins) as Inhibitors of Cytochrome P450 2C8. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005, 97, 104-108.	1.2	34
129	Metabolism of Repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of Fibrates and Rifampicin. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005, 97, 249-256.	1.2	149
130	Effect of Itraconazole on the Pharmacokinetics of Atenolol. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005, 97, 395-398.	1.2	11
131	Cyclosporine A monitoring ? how to account for twice and three times daily dosing. <i>Pediatric Nephrology</i> , 2005, 20, 591-596.	0.9	6
132	Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 390-396.	1.1	35
133	The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 441-447.	1.1	81
134	Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 349-353.	1.1	84
135	Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 331-341.	2.3	98
136	Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 239-249.	2.3	80
137	Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 598-606.	2.3	130
138	High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). <i>Pharmacogenetics and Genomics</i> , 2004, 14, 429-440.	5.7	391
139	Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 192-198.	2.3	126
140	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. <i>Diabetologia</i> , 2003, 46, 347-351.	2.9	269
141	Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. <i>Diabetologia</i> , 2003, 46, 1319-1323.	2.9	167
142	Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 538-544.	2.3	170
143	Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 25-31.	2.3	20
144	Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 380-387.	2.3	154

#	ARTICLE	IF	CITATIONS
145	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 427-432.	1.1	40
146	Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2003, 57, 181-187.	1.1	66
147	Pharmacokinetic Interactions with Rifampicin. <i>Clinical Pharmacokinetics</i> , 2003, 42, 819-850.	1.6	591
148	Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes. <i>Drug Metabolism and Disposition</i> , 2002, 30, 1352-1356.	1.7	174
149	Effect of Albumin and Cytosol on Enzyme Kinetics of Tolbutamide Hydroxylation and on Inhibition of CYP2C9 by Gemfibrozil in Human Liver Microsomes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 302, 43-49.	1.3	19
150	Trimethoprim and Sulfamethoxazole are Selective Inhibitors of CYP2C8 and CYP2C9, Respectively. <i>Drug Metabolism and Disposition</i> , 2002, 30, 631-635.	1.7	141
151	Dose Optimization of a Doxorubicin Prodrug (HMR 1826) in Isolated Perfused Human Lungs: Low Tumor pH Promotes Prodrug Activation by $\beta$ -Glucuronidase. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 301, 223-228.	1.3	51
152	Expression of active human $\beta$ -glucuronidase in Sf9 cells infected with recombinant baculovirus. <i>Life Sciences</i> , 2002, 71, 1547-1557.	2.0	5
153	Isoniazid is a mechanism-based inhibitor of cytochrome P 450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. <i>European Journal of Clinical Pharmacology</i> , 2002, 57, 799-804.	0.8	143
154	Gemfibrozil greatly increases plasma concentrations of cerivastatin. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 685-691.	2.3	296
155	Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 37-42.	0.8	37
156	Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 399-407.	1.1	18
157	In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 547-553.	1.1	131
158	Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 194-200.	2.3	59
159	Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 340-345.	2.3	174
160	Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 400-406.	2.3	104
161	Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2001, 48, 881-885.	1.3	69
162	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 591-595.	1.1	46

#	ARTICLE	IF	CITATIONS
163	Platelet dysfunction after intravenous ketorolac or propacetamol. <i>Acta Anaesthesiologica Scandinavica</i> , 2000, 44, 69-74.	0.7	66
164	Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 215-221.	2.3	45
165	Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 382-390.	2.3	42
166	Plasma concentrations of active simvastatin acid are increased by gemfibrozil. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 122-129.	2.3	235
167	The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 487-494.	2.3	105
168	Rifampin decreases the plasma concentrations and effects of repaglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 495-500.	2.3	91
169	Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 592-597.	2.3	132
170	Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. <i>European Journal of Clinical Pharmacology</i> , 2000, 56, 225-229.	0.8	111
171	Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life. <i>European Journal of Clinical Pharmacology</i> , 2000, 56, 411-415.	0.8	85
172	Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 45, 701-704.	1.3	66
173	Midazolam Hydroxylation by Human Liver Microsomes <i>in vitro</i> : Inhibition by Calcium Channel Blockers, Itraconazole and Ketoconazole. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999, 85, 157-161.	0.0	56
174	Fluvoxamine is a More Potent Inhibitor of Lidocaine Metabolism than Ketoconazole and Erythromycin <i>in vitro</i> . <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999, 85, 201-205.	0.0	32
175	Itraconazole Decreases the Clearance and Enhances the Effects of Intravenously Administered Methylprednisolone in Healthy Volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999, 85, 29-32.	0.0	53
176	Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 448-453.	2.3	59
177	Immunohistochemical detection of microsomal epoxide hydrolase in human synovial tissue. <i>The Histochemical Journal</i> , 1999, 31, 645-649.	0.6	3
178	Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam*1. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 401-407.	2.3	33
179	Grapefruit juice substantially increases plasma concentrations of buspirone*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 655-660.	2.3	119
180	Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: Differential elevation of cyclooxygenase 2 in inflammatory joint diseases. <i>Arthritis and Rheumatism</i> , 1998, 41, 122-129.	6.7	191

#	ARTICLE	IF	CITATIONS
181	The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. <i>European Journal of Clinical Pharmacology</i> , 1998, 54, 53-58.	0.8	246
182	The Role of $\beta$ -Glucuronidase in Drug Disposition and Drug Targeting in Humans. <i>Clinical Pharmacokinetics</i> , 1997, 33, 18-31.	1.6	153
183	Triazolam is ineffective in patients taking rifampin. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 61, 8-14.	2.3	96
184	Concentrations and Effects of Oral Midazolam are Greatly Reduced in Patients Treated with Carbamazepine or Phenytoin. <i>Epilepsia</i> , 1996, 37, 253-257.	2.6	133
185	Rifampin drastically reduces plasma concentrations and effects of oral midazolam. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 7-13.	2.3	219
186	Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 55, 481-485.	2.3	386
187	Dose of midazolam should be reduced during diltiazem and verapamil treatments.. <i>British Journal of Clinical Pharmacology</i> , 1994, 37, 221-225.	1.1	164